HAHSTA - FY14 Pharmaceutical Services

The District of Columbia's HIV/AIDS, Hepatitis, STD, and Tuberculosis Administration (HAHSTA) is seeking pharmaceutical services for fiscal year 2014, as indicated by the contract opportunity with ID 66c85cbd829eb5d869074212. This procurement appears to be focused on acquiring comprehensive pharmaceutical support for the agency's healthcare programs, specifically targeting HIV/AIDS-related medical treatments and services. The contract was posted and due on April 24, 2014, suggesting an expedited procurement process with an immediate need for pharmaceutical service providers. While specific detailed requirements are not fully elaborated in the provided document, the procurement likely involves the delivery of pharmaceutical products, potential management of drug inventories, and supporting healthcare services related to HIV/AIDS treatment. The procurement seems targeted at healthcare providers, pharmaceutical companies, or specialized medical service vendors with experience in managing complex pharmaceutical supply chains for public health programs.

The contract opportunity does not explicitly specify set-aside designations or provide clear information about disadvantaged enterprise requirements. Without additional context, it is difficult to determine precise restrictions on potential bidders or respondents. The document lacks specific details about incumbent vendors, existing technological infrastructure, or precise award values. The fiscal year 2014 timeframe suggests this was a time-sensitive procurement with potential budget allocations specific to that year's healthcare funding. Given the nature of HAHSTA's mission, the contract likely involved significant pharmaceutical procurement with potential annual values ranging from hundreds of thousands to potentially several million dollars, depending on the scope of HIV/AIDS treatment services required by the District of Columbia.